Celebrating ten years of success 2004-2014
Special summit of African Union on HIV and Aids, Tuberculosis and Malaria (atm) Abuja, Nigeria 2–4 may, 2006Sp/Assembly/ATM/2 (I), Rev.3
Abuja call for accelerated action towards universal access to HIV and Aids, Tuberculosis and Malaria services in Africa
UNHCR, the UN Refuge Agency, and NGO partners are launching an appeal for US$2.7 billion to address the live-saving humanitarian needs of South Sudanese refugees in 2019 and 2020.
Five years on since the onset of a brutal civil war, over 2.2 million South Sudanese refugees have sought safety in six... neighboring countries Uganda, Sudan, Ethiopia, Kenya, the Democratic Republic of the Congo (DRC) and Central African Republic (CAR). Another 1.9 million remain internally displaced inside South Sudan
more
Strengthening HIV prevention among most-at-risk populations (MARPs) in the Syrian Arab Republic:
Examination of the business behaviour of Boehringer Ingelheim, Bayer and Baxter in Uganda
The occurrence of a high percentage of couterfeit medicines on the global medicines market is often attributed to a lack of effective regulation and a weak enforcement capacity. This review, while focusing on counterfeit medicines and medical devices in developing countries, will present information... on their impact and how these issues can be addressed by regulation and control of the supply chain using technology appropriate to the developing world.
more
Journal of Social Work in Developing Societies 13
Vol. 2(1): 13-25 , June 2020
Despite high regional demand for vaccines valued at over US$ 1 billion annually, Africa’s vaccine industry provides only 0.1% of global supply. Vaccine inequity and hoarding at the start of the pandemic, which resulted in delays in obtaining COVID-19 doses, stimulated new resolve to address future... supply security. In 2021, the AU set a target to produce and supply more than 60% of the vaccine doses on the continent by 2040.
In the last 18 months alone, more than 30 new African manufacturing projects have been announced and estimates indicate that the African vaccine market across all existing and projected novel products could range between US$ 2.8 billion and US$ 5.6 billion by 2040*, demonstrating the potential for a thriving regional industry to emerge.
more